title: [Effect of change to flutamide for prostate cancer patient who developed breast pain during bicalutamide treatment (BIP-F study)].
abstract: In Japan, prostate cancer is treated with non-steroidal anti-androgen (flutamide and bicalutamide). Development of breast pain during bicalutamide treatment, in prostate cancer patients reduces their quality of life (QOL) and treatment compliance. We studied the safety and effectiveness of switching from bicalutamide to flutamide in 13 prostate cancer patients who developed breast pain during bicalutamide treatment. We estimated the change in breast pain using a face scale and the Expanded Prostate Cancer Index Composite (EPIC) and EPIC-hormone domain (HD) score. The switch to flutamide relieved breast pain in nine patients, had no effect in one patient, and increased breast pain in two patients. One patient dropped out. Furthermore, summary score and hormone function were improved with a significant difference in the EPIC-HD score. Switching to flutamide in prostate cancer patients who develop breast pain during bicalutamide is safe and effective.
authors.affiliation: The Department of Urology, National Hospital Organization Kyoto Medical Center.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Kitamura
authors.affiliation: The Department of Urology, National Hospital Organization Kyoto Medical Center.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Okuno
authors.affiliation: The Department of Urology, National Hospital Organization Kyoto Medical Center.
authors.forename: Yuma
authors.initials: Y
authors.lastname: Sakura
authors.affiliation: The Department of Urology, National Hospital Organization Kyoto Medical Center.
authors.forename: Yumi
authors.initials: Y
authors.lastname: Manabe
authors.affiliation: The Department of Urology, National Hospital Organization Kyoto Medical Center.
authors.forename: Norihiko
authors.initials: N
authors.lastname: Masuda
authors.affiliation: The Department of Urology, National Hospital Organization Kyoto Medical Center.
authors.forename: Haruk
authors.initials: H
authors.lastname: Ito
authors.affiliation: The Department of Urology, National Hospital Organization Kyoto Medical Center.
authors.forename: Mutsuki
authors.initials: M
authors.lastname: Mishina
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Rikiya
authors.initials: R
authors.lastname: Taoka
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Akito
authors.initials: A
authors.lastname: Terai
authors.affiliation: The Department of Urology, Kagawa University.
authors.forename: Mikio
authors.initials: M
authors.lastname: Sugimoto
authors.affiliation: The Department of Urology, Kagawa University.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kakehi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D000813:Anilides / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D004334:Drug Administration Schedule; D057915:Drug Substitution; D005485:Flutamide / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D059373:Mastodynia / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control*; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects*; D010147:Pain Measurement / Q000379:methods; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D014105:Tosyl Compounds / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; D005485:Flutamide; C053541:bicalutamide